ATLANTA--(BUSINESS WIRE)--
Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE: TEVA) American Depositary Shares (“ADSs”) on the New York Stock Exchange and/or common stock on the Tel Aviv Stock Exchange (“TASE”) between November 15, 2016 and August 2, 2017. The complaint alleges Teva issued false and misleading statements during that time.
Specifically, the Complaint alleges Teva failed to disclose the poor performance of its U.S. generics business and the subsequent goodwill impairment charge stemming from the Company’s purchase of Actavis Generics. On August 3, 2017, Teva announced a $6.1 million goodwill impairment charge in the second quarter of 2016. The price of Teva common stock has declined following the report.
If you purchased Teva shares between November 15, 2016 and August 2, 2017 and suffered losses on that investment, you are encouraged to visit the firm’s website at www.holzerlaw.com to receive additional information about your legal rights. You can also contact Corey D. Holzer, Esq. at [email protected] or Alexandria P. Rankin, Esq. at [email protected], or call the firm by toll-free telephone at (888) 508-6832 for more information. The case is pending in the United States District Court for the Eastern District of Pennsylvania and the deadline to move for appointment as lead plaintiff is October 23, 2017.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005729/en/
